Clinical Trial Update: Ketoconazole, Hydrocortisone, Dutasteride and Lapatinib (KHAD-L) in Prostate Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial KHAD-L regimen (ketoconazole, hydrocortisone, dutasteride, lapatinib) in prostate cancer has been terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• DUTASTERIDE (Dutasteride)
• HYDROCORTISONE (HYDROCORTISONE)
• Ketoconazole (Ketoconazole)
• Lapatinib (Lapatinib)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Prostate Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2018-09-04